Revisiting the standard blueprint for biomarker development to address emerging cancer early detection technologies
Open Access
- 6 November 2023
- journal article
- editorial
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 116 (2) , 189-193
Abstract
Novel liquid biopsy technologies are creating a watershed moment in cancer early detection. Evidence supporting population screening is nascent, but a rush to market the new tests is prompting cancer early detection researchers to revisit the standard blueprint that the Early Detection Research Network established to evaluate novel screening biomarkers. In this commentary, we review the Early Detection Research Network’s Phases of Biomarker Development (PBD) for rigorous evaluation of novel early detection biomarkers and discuss both hazards and opportunities involved in expedited evaluation. According to the PBD, for a biomarker-based test to be considered for population screening, 1) test sensitivity in a prospective screening setting must be adequate, 2) the shift to early curable stages must be meaningful, and 3) any stage shift must translate into clinically significant mortality benefit. In the past, determining mortality benefit has required lengthy randomized screening trials, but interest is growing in expedited trial designs with shorter-term endpoints. Whether and how best to use such endpoints in a manner that retains the rigor of the PBD remains to be determined. We discuss how computational disease modeling can be harnessed to learn about screening impact and meet the needs of the moment.Keywords
Funding Information
- Rosalie and Harold Rea Brown Endowed Chair
- National Cancer Institute (R35CA274442)
- Early Detection Research Network Data Management and Coordinating Center
This publication has 46 references indexed in Scilit:
- Estimation of Benefits, Burden, and Harms of Colorectal Cancer Screening StrategiesJAMA, 2016
- Collaborative Modeling of the Benefits and Harms Associated With Different U.S. Breast Cancer Screening StrategiesAnnals of Internal Medicine, 2016
- Models in the Development of Clinical Practice GuidelinesAnnals of Internal Medicine, 2014
- Benefits and Harms of Computed Tomography Lung Cancer Screening Strategies: A Comparative Modeling Study for the U.S. Preventive Services Task ForceAnnals of Internal Medicine, 2014
- Comparative Effectiveness of Alternative Prostate-Specific Antigen–Based Prostate Cancer Screening StrategiesAnnals of Internal Medicine, 2013
- Clarifying Differences in Natural History between Models of ScreeningMedical Decision Making, 2011
- A Systematic Comparison of Microsimulation Models of Colorectal CancerMedical Decision Making, 2011
- Cumulative Incidence of False-Positive Results in Repeated, Multimodal Cancer ScreeningThe Annals of Family Medicine, 2009
- Evaluating Test Strategies for Colorectal Cancer Screening: A Decision Analysis for the U.S. Preventive Services Task ForceAnnals of Internal Medicine, 2008
- Trial Design Based on Surrogate End Points--Application to Comparison of Different Breast Screening FrequenciesJournal of the Royal Statistical Society Series A: Statistics in Society, 1996